Only in Titles

           Search results for: Mouse anti humanPDGFR-alpha Anti-Human antibodies   

paperclip

#30631444   // Save this To Up

Inflammatory cell expression of Toll-like receptor-2 (TLR2) within refractory periapical granuloma.

Toll-like receptor-2 (TLR2) is highly important within the immune system. Characterization of the expression of TLR2 within inflammatory cells in periapical lesions could help in diagnosis and management of refractory cases. The aim of the study is identification of Toll-like receptor (TLR2) through immunohistochemical and immunofluroscence expression in inflammatory cells within refractory periapical granuloma cases. Eight cases of refractory periapical granuloma were selected out of 772 cases. Histological examination and immunohistochemical staining with polyclonal rabbit antihuman TLR2, monoclonal mouse antihuman CD38, CD68 and CD83 primary antibodies, as well as immunofluorescence staining with goat anti-rabbit TLR2, donkey anti-mouse CD38, CD68 and CD83 primary antibodies was conducted. Positive controls, negative controls and experimental sections with no primary antibody were included in the study. Qualitative analysis and double immunofluorescence technique was used to characterize the TLR cells. In periapical granuloma, lymphocytes (CD38 cells) expressed the most amount of TLR reactivity followed by macrophages (CD68 cells), and odontogenic epithelial cells. Neutrophils, red blood cells (RBCs) and collagen ground substance were negative to TLR2.  TLR2 was highly expressed by lymphocytes and plasma cells indicative of their major role in the inflammatory process and antigen recognition in refractory periapical granuloma. Dendritic cells expressing TLR2 were low in number suggesting a minor role in sustaining these lesions.

2838 related Products with: Inflammatory cell expression of Toll-like receptor-2 (TLR2) within refractory periapical granuloma.

Rat Toll Like Receptor 2( Rat monoclonal anti mouse Human Killer cell immunog B5 Receptor PCID1 EIF3M  CytoX Violet Cell Proli Polyclonal Antibody Prote ATP6IP2 Renin receptor pCMVbeta Mammalian lacZnl MTT Cell Proliferation As pCAMBIA0380 Vector (No Re Androgen Receptor Competent Cells for Cloni

Related Pathways

paperclip

#30548114   // Save this To Up

Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.

L-Type amino acid transporter 1 (LAT1) disulfide linked to CD98 heavy chain (hc) is highly expressed in most cancer cells, but weakly expressed in normal cells. In the present study, we developed novel anti-LAT1 mAbs and showed internalization activity, inhibitory effects of amino acid uptake and cell growth and antibody-dependent cellular cytotoxicity, as well as in vivo antitumor effects in athymic mice. Furthermore, we examined the reactivity of mAbs with LAT1 of Macaca fascicularis to evaluate possible side-effects of antihuman LAT1 mAbs in clinical trials. Antihuman LAT1 mAbs reacted with ACHN human and MK.P3 macaca kidney-derived cells, and this reactivity was significantly decreased by siRNAs against LAT1. Macaca LAT1 cDNA was cloned from MK.P3, and only two amino acid differences between human and macaca LAT1 were seen. RH7777 rat hepatoma and HEK293 human embryonic kidney cells expressing macaca LAT1 were established as stable transfectants, and antihuman LAT1 mAbs were equivalently reactive against transfectants expressing human or macaca LAT1. Dual (high and low) avidity modes were detected in transfectants expressing macaca LAT1, MK.P3, ACHN and HCT116 human colon cancer cells, and K values were increased by anti-CD98hc mAb, suggesting anti-LAT1 mAbs detect an epitope on LAT1-CD98hc complexes on the cell surface. Based on these results, LAT1 may be a promising anticancer target and Macaca fascicularis can be used in preclinical studies with antihuman LAT1 mAbs.

1075 related Products with: Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.

Anti Mouse asc type Amino Rabbit Anti-PIWIL4 Polycl ELHGBI Human Monkey IgG a Human monkey anti-bovine Human monkey anti-human t Human monkey anti-porcine Human monkey anti-human t Rabbit Anti-TPST2 Polyclo Rabbit Anti-EDG1 CD363 Po Rabbit Anti-ASM Acid sphi Human monkey anti-chick t Human monkey anti-porcine

Related Pathways

paperclip

#28384052   // Save this To Up

PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.

Podocalyxin (PODXL) is a CD34-related sialomucin and a well-known marker of embryonic stem cells. PODXL is expressed in many types of tumors including colorectal cancers, breast cancers, and brain tumors. Overexpression of PODXL is an independent predictor of progression, metastasis, and poor outcome. PODXL is also expressed in many normal cells such as renal podocytes and endothelial cells (ECs). However, high-sensitive and high-specific anti-PODXL monoclonal antibodies (mAbs) have not been established. Herein, we immunized mice with recombinant human PODXL, which was produced using LN229 glioblastoma cells. The anti-PODXL mAb, PcMab-47, reacted with endogenous PODXL-expressing cancer cell lines and normal cells independently of glycosylation in flow cytometry. Immunohistochemical analysis showed that PcMab-47 detected PODXL-expressing normal cells such as podocytes of kidney or ECs. Furthermore, PcMab-47 stained PODXL-expressing cancer cells of colon or breast cancers. These results suggest that PcMab-47 could be useful for investigating the expression and function of PODXL in cancers and normal tissues.

1542 related Products with: PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.

MOUSE ANTI CANINE DISTEMP MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI HUMAN CD19 RPE MOUSE ANTI APAAP COMPLEX, MOUSE ANTI BORRELIA BURGD MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI BOVINE ROTAVIR ROR1 monoclonal antibody Mouse Anti-BrdU(A7) Monoc Monoclonal Anti-Bacterial Monoclonal Anti-Aurora-A Mouse Anti-IFN gamma(F2E4

Related Pathways

paperclip

#28332312   // Save this To Up

Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.

Human podoplanin (hPDPN), a platelet aggregation-inducing transmembrane glycoprotein, is expressed in different types of tumors, and it binds to C-type lectin-like receptor 2 (CLEC-2). The overexpression of hPDPN is involved in invasion and metastasis. Anti-hPDPN monoclonal antibodies (mAbs) such as NZ-1 have shown antitumor and antimetastatic activities by binding to the platelet aggregation-stimulating (PLAG) domain of hPDPN. Recently, we developed a novel mouse anti-hPDPN mAb, LpMab-2, using the cancer-specific mAb (CasMab) technology. In this study we developed chLpMab-2, a human-mouse chimeric anti-hPDPN antibody, derived from LpMab-2. chLpMab-2 was produced using fucosyltransferase 8-knockout (KO) Chinese hamster ovary (CHO)-S cell lines. By flow cytometry, chLpMab-2 reacted with hPDPN-expressing cancer cell lines including glioblastomas, mesotheliomas, and lung cancers. However, it showed low reaction with normal cell lines such as lymphatic endothelial and renal epithelial cells. Moreover, chLpMab-2 exhibited high antibody-dependent cellular cytotoxicity (ADCC) against PDPN-expressing cells, despite its low complement-dependent cytotoxicity. Furthermore, treatment with chLpMab-2 abolished tumor growth in xenograft models of CHO/hPDPN, indicating that chLpMab-2 suppressed tumor development via ADCC. In conclusion, chLpMab-2 could be useful as a novel antibody-based therapy against hPDPN-expressing tumors.

1562 related Products with: Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.

Rabbit Anti-IEX1 Differen Rabbit Anti-Nkx2.5 Cardia anti CD20 monoclonal anti Rabbit Anti-IEX1 Differen MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI HUMAN CD19 RPE PABP1-dependent poly A-sp Rabbit Anti-phospho-TIRAP Cytokine (Human) Antibody Mouse Anti-Human Akt (PKB Rabbit Anti-RIP1 Polyclon

Related Pathways

paperclip

#27861291   // Save this To Up

Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.

Graft-versus-host disease (GVHD) is a severe complication of hematopoietic stem cell transplantation. Current therapies to prevent alloreactive T cell activation largely cause generalized immunosuppression and may result in adverse drug, antileukemia and antipathogen responses. Recently, several immunomodulatory therapeutics have been developed that show efficacy in maintaining antileukemia responses while inhibiting GVHD in murine models. To analyze efficacy and better understand immunological tolerance, escape mechanisms, and side effects of clinical reagents, testing of species cross-reactive human agents in large animal GVHD models is critical.

2893 related Products with: Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.

Small intestine disease ( Small cell lung carcinoma Integrin â3 (Ab 785) Ant Integrin â3 (Ab 773) Ant Lung small cell carcinoma Interleukin-34 IL34 (N-t Polyclonal Antibody Recep Polyclonal Antibody Inter Integrin â3 (Phospho Tyr Small intestine disease s Non small cell lung carci HIV1 integrase antibody,

Related Pathways

paperclip

#27763797   // Save this To Up

Expression of TRAIL and Fas in Primary Hyperparathyroidism.

Differentiating between parathyroid lesions is still difficult and ambiguous. In cases of primary hyperparathyroidism, appropriate and prompt diagnosis is of great importance for effective treatment and follow-up. A great amount of mechanisms contribute to the pathogenesis of primary hyperparathyroidism, such as disturbance in balance between pro- and anti-apoptotic factors. Therefore, we examined whether immunohistochemical expression of apoptotic factors, TNF-related apoptosis-inducing ligand (TRAIL) and Fas, could have clinical utility as a marker of proliferative lesions of parathyroid gland.

1592 related Products with: Expression of TRAIL and Fas in Primary Hyperparathyroidism.

FASLG & MAPK8 Protein Pro DNA (cytosine 5) methyltr Primary antibody Trail A MarkerGeneTM Live Dead As MAPK8 & FASLG Protein Pro FASLG & PIK3R1 Protein Pr FASLG & FYN Protein Prote FADD & FASLG Protein Prot Goat Anti-Mouse Fascin 2, Primary antibody FLIP An FAS & FASLG Protein Prote pCAMBIA0105.1R Vector, (G

Related Pathways

paperclip

#26825708   // Save this To Up

A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

The primary B-cell epitopes of factor VIII (fVIII) are in the A2 and C2 domains. Within the C2 domain, antibody epitope and kinetics are more important than inhibitor titer in predicting pathogenicity in a murine bleeding model. To investigate this within the A2 domain, the pathogenicity of a diverse panel of antihuman fVIII A2 domain monoclonal antibodies (MAbs) was tested in the murine model. MAbs were injected into hemophilia A mice, followed by injection of human B domain-deleted fVIII. Blood loss after a 4-mm tail snip was measured. The following anti-A2 MAbs were tested: high-titer type 1 inhibitors 4A4, 2-76, and 1D4; 2-54, a high-titer type 2 inhibitor; B94, a type 2 inhibitor; and noninhibitory MAbs GMA-012, 4C7, and B25. All high-titer type 1 MAbs produced blood loss that was significantly greater than control mice, whereas all non-inhibitory MAbs produced blood loss that was similar to control. The type 2 MAbs were not pathogenic despite 2-54 having an inhibitor titer of 34 000 BU/mg immunoglobulin G. In addition, a patient with a high-titer type 2 anti-A2 inhibitor who is responsive to fVIII is reported. The discrepancy between inhibitor titer and bleeding phenotype combined with similar findings in the C2 domain stress the importance of inhibitor properties not detected in the standard Bethesda assay in predicting response to fVIII therapy.

2241 related Products with: A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

Mouse Anti-Human Factor V Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F Mouse Anti-Human Factor V Rabbit Anti-factor VIII(F Rabbit Anti-factor VIII(F

Related Pathways

paperclip

#26505555   // Save this To Up

Matrix interference from Fc-Fc interactions in immunoassays for detecting human IgG4 therapeutics.

An assay measuring an IgG4 biotherapeutic in human serum used a drug-specific monoclonal antibody (mAb) capture reagent and an antihuman IgG4 mAb as detection reagent. However, serum IgG4 binding to the capture mAb via Fc-interactions was detected by the anti-IgG4 mAb, causing high background.

1488 related Products with: Matrix interference from Fc-Fc interactions in immunoassays for detecting human IgG4 therapeutics.

Goat Anti-Human Neuroligi Goat Anti-Human PPID CyP- Cytokine (Human) Antibody Recombinant Human Interle Anti human C1 Esterase In Goat Anti-Human TUSC4 NPR Goat Anti-Human MAOB, (in Goat Anti-Human GCC185, ( Cytokine (Human) Antibody Goat Anti-Human FRA1 FOSL Goat Anti-Human Urocortin Isopeptidase T (long form

Related Pathways

paperclip

#24956206   // Save this To Up

Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin.


1073 related Products with: Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin.

Rabbit Anti-Human NFkB In Mouse anti human Integrin Cytokine (Human) Antibody Goat Anti-Human ZDHHC8, ( Goat Anti-Human Prolyl En Goat Anti-Human MSH5, (in Goat Anti-Human Glutathio Goat Anti-Human RNASEN Dr Goat Anti-Human KCC3 SLC1 Goat Anti-Human Apolipopr Goat Anti- Notch1a (zebra Goat Anti-Human GOT1 (aa

Related Pathways

  •  
  • No related Items
paperclip

#24866768   // Save this To Up

Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).

Endoglin (ENG) is a TGF-β coreceptor and essential for vascular development and angiogenesis. A chimeric antihuman ENG (hENG) monoclonal antibody (mAb) c-SN6j (also known as TRC105) shows promising safety and clinical efficacy features in multiple clinical trials of patients with various advanced solid tumors. Here we developed a novel genetically engineered mouse model to optimize the ENG-targeting clinical trials. We designed a new targeting vector that contains exons 4-8 of hENG gene to generate novel genetically engineered mice (GEMs) expressing functional human/mouse chimeric (humanized) ENG with desired epitopes. Genotyping of the generated mice confirmed that we generated the desired GEMs. Immunohistochemical analysis demonstrated that humanized ENG protein of the GEMs expresses epitopes defined by 7 of our 8 anti-hENG mAbs tested. Surprisingly the homozygous GEMs develop normally and are healthy. Established breast and colon tumors as well as metastasis and tumor microvessels in the GEMs were effectively suppressed by systemic administration of anti-hENG mAbs. Additionally, test result indicates that synergistic potentiation of antitumor efficacy can be induced by simultaneous targeting of two distinct epitopes by anti-hENG mAbs. Sorafenib and capecitabine also showed antitumor efficacy in the GEMs. The presented novel GEMs are the first GEMs that express the targetable humanized ENG. Test results indicate utility of the GEMs for the clinically relevant studies. Additionally, we generated GEMs expressing a different humanized ENG containing exons 5-6 of hENG gene, and the homozygous GEMs develop normally and are healthy.

2984 related Products with: Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).

Mouse anti human Endoglin Rabbit anti sCD105 Endogl Rat anti sCD105 Endoglin Rabbit anti sCD105 Endogl Rat anti sCD105 Endoglin- Monoclonal Anti-Breast Ca Rabbit Anti-Human Endogli Mouse Anti-Insulin-Like G Mouse Anti-Human CD105 An Rabbit anti sCD105 Endogl Mouse Anti-Human CD105 An Recombinant Mouse Endogli

Related Pathways